clinical trial · NCT05813288
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)
Areteia Therapeutics·phase3·terminated·n = 654
Eosinophilic AsthmaAsthma; EosinophilicAsthmaDexpramipexole DihydrochloridePlacebo
brief summary
The objective of this clinical study is to investigate the safety, tolerability, and efficacy of dexpramipexole in participants with inadequately controlled severe eosinophilic asthma.
started
Mar 27, 2023
primary completion
Dec 8, 2025
completion
Dec 8, 2025
last updated
Dec 15, 2025
official title
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Dexpramipexole Administered Orally for 52 Weeks in Participants With Severe Eosinophilic Asthma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol